Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-08-13
Study Completion Date
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulsed Field Ablation vs Cryoablation In Paroxysmal Atrial Fibrillation
NCT05940597
Atrial Fibrillation Paroxysmal
ACTIVE_NOT_RECRUITING
NA
Assessment of Pulmonary Vein Isolation Using a Balloon Catheter With Pulsed Field Energy in Atrial Fibrillation
NCT07156877
Atrial Fibrillation (AF)
NOT_YET_RECRUITING
NA
A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy
NCT00773539
Atrial Fibrillation Ablation
UNKNOWN
PHASE4
Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation
NCT02344394
Persistent Atrial Fibrillation
WITHDRAWN
NA
Cryoballoon PVI With PWI Versus PVI Alone In Patients With PAF
NCT05296824
Paroxysmal Atrial Fibrillation
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Course of ablation. All ablations will be performed using Medtronic Arctic Front Advance catheter system as well as future generations of Medtronic cryoballoon catheter systems.
Initially the cryoenergy will be delivered without previous venography confirming full vein occlusion. Then, in case of vein isolation failure after 5 minutes of cryoenergy delivery, further attempts to isolate the vein will be preceded by venography.
Statistical analysis. The assumed sample size (N = 50 patients/ 200 veins) will allow to estimate the number and percentage of pulmonary veins that will be isolated without the use of contrast.
The statistical analysis will use standard descriptive statistics tools: frequency tables for categorical variables; extreme values, mean value and standard deviation for normal distributed variables; and extreme values and quartiles for non-normal distributed variables.
Parameters assessed during the procedure:
Concerning a single energy cryoapplication
1. Possibility of registration (occurrence vs. non-occurrence) of pulmonary vein potentials before the cryoapplication, and after the occlusion of the vein by the balloon.
2. Time to vein isolation
3. Cryoenergy application time / freezing time
4. The minimum temperature obtained during cryoapplication
5. Time to obtain temperature - 30 ° C and - 40 ° C
6. Temperature after 30, 60 and 90 seconds from the beginning of cryoenergy application
7. Cryoballoon heating time from -30 C to +15 C Concerning the isolation of a single vein
8. Total time to complete isolation of a vein
9. The number of cryoenergy applications
10. Total time of cryoenergy application per vein
Concerning the entire procedure:
11. Total cryoenergy application time per procedure / patient
12. The total amount of contrast
13. Radiation dose
14. Time of radiation
15. Left atrial dwelling time
16. Duration of the procedure (from puncture of the vein to sheaths removal)
Termination of cryoenergy delivery:
1. If temperature does not reach - 30 ° C after 60 seconds of cryoenergy application (inefficient application).
2. If vein isolation does not occur after 90 seconds of cryoenergy application (inefficient application).
3. If temperature after 30 seconds of cryoapplication falls lower than - 50° C (unsafe application).
4. When temperature reaches - 55° C (unsafe application).
5. If phrenic nerve injury occurs or if symptoms suggesting its imminent occurrence are noticed (unsafe application).
6. If the operator considers that the application is ineffective or performed too distally (inefficient or unsafe application).
Effective cryoenergy applications will be terminated 120 seconds after vein isolation.
Veins with no recordable pulmonary vein potentials - The above-mentioned veins will be isolated - 1 application 240 seconds. Applications will be considered effective if the minimum temperature achieved will be less than 35C and the stimulation performed from the vein after application will be ineffective.
Supplemental cryoapplications. Supplemental cryoenergy applications will not be delivered after successful isolation of the vein
Vein isolation assessment. Pulmonary vein isolation will be assessed by demonstrating entrance and exit block
Phrenic nerve function monitoring. In order to prevent PN injury/ palsy the balloon will be inflated outside PV ostia and maintained as antrally as possible during vein isolation. For phrenic nerve function monitoring pacing of the nerve during right pulmonary vein isolation will be performed. Additionally, intermittent fluoroscopy during pacing will be used for monitoring diaphragmatic motion. The ablation will be stopped at the first sign of imminent phrenic nerve injury.
Complications assessed. Transient phrenic nerve injury or palsy (resolving until discharge after index procedure) is considered a minor complication. Death, stroke, tamponade, arteriovenous fistula or pseudoaneurysm, persistent (resolving during follow up) or permanent (if not resolved at end of follow up, but \>12 months) phrenic nerve palsy, bleeding with a decrease in haemoglobin of at least 2 g / dl or any other state requiring prolongation of hospitalization are considered major complications.
The duration of the project and follow-up. The study is expected to last two years. Approximately 50 patients will be enrolled, with one year follow-up. All patients will have follow-up visits in an out-patient clinic at least 3 and 12 months post PVI. Additionally at 6 weeks, 6 and 9 months post ablation telephone follow-up will be conducted by the study coordinator using standardized questionnaire.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Course of ablation. All ablations will be performed using Medtronic Arctic Front Advance catheter system as well as future generations of Medtronic cryoballoon catheter systems.
Initially the cryoenergy will be delivered without previous venography confirming full vein occlusion. Then, in case of vein isolation failure after 5 minutes of cryoenergy delivery, further attempts to isolate the vein will be preceded by venography.
Statistical analysis. The assumed sample size (N = 50 patients/ 200 veins) will allow to estimate the number and percentage of pulmonary veins that will be isolated without the use of contrast.
The statistical analysis will use standard descriptive statistics tools: frequency tables for categorical variables; extreme values, mean value and standard deviation for normal distributed variables; and extreme values and quartiles for non-normal distributed variables.
Parameters assessed during the procedure:
Concerning a single energy cryoapplication
1. Possibility of registration (occurrence vs. non-occurrence) of pulmonary vein potentials before the cryoapplication, and after the occlusion of the vein by the balloon.
2. Time to vein isolation
3. Cryoenergy application time / freezing time
4. The minimum temperature obtained during cryoapplication
5. Time to obtain temperature - 30 ° C and - 40 ° C
6. Temperature after 30, 60 and 90 seconds from the beginning of cryoenergy application
7. Cryoballoon heating time from -30 C to +15 C Concerning the isolation of a single vein
8. Total time to complete isolation of a vein
9. The number of cryoenergy applications
10. Total time of cryoenergy application per vein
Concerning the entire procedure:
11. Total cryoenergy application time per procedure / patient
12. The total amount of contrast
13. Radiation dose
14. Time of radiation
15. Left atrial dwelling time
16. Duration of the procedure (from puncture of the vein to sheaths removal)
Termination of cryoenergy delivery:
1. If temperature does not reach - 30 ° C after 60 seconds of cryoenergy application (inefficient application).
2. If vein isolation does not occur after 90 seconds of cryoenergy application (inefficient application).
3. If temperature after 30 seconds of cryoapplication falls lower than - 50° C (unsafe application).
4. When temperature reaches - 55° C (unsafe application).
5. If phrenic nerve injury occurs or if symptoms suggesting its imminent occurrence are noticed (unsafe application).
6. If the operator considers that the application is ineffective or performed too distally (inefficient or unsafe application).
Effective cryoenergy applications will be terminated 120 seconds after vein isolation.
Veins with no recordable pulmonary vein potentials - The above-mentioned veins will be isolated - 1 application 240 seconds. Applications will be considered effective if the minimum temperature achieved will be less than 35C and the stimulation performed from the vein after application will be ineffective.
Supplemental cryoapplications. Supplemental cryoenergy applications will not be delivered after successful isolation of the vein
Vein isolation assessment. Pulmonary vein isolation will be assessed by demonstrating entrance and exit block
Phrenic nerve function monitoring. In order to prevent PN injury/ palsy the balloon will be inflated outside PV ostia and maintained as antrally as possible during vein isolation. For phrenic nerve function monitoring pacing of the nerve during right pulmonary vein isolation will be performed. Additionally, intermittent fluoroscopy during pacing will be used for monitoring diaphragmatic motion. The ablation will be stopped at the first sign of imminent phrenic nerve injury.
Complications assessed. Transient phrenic nerve injury or palsy (resolving until discharge after index procedure) is considered a minor complication. Death, stroke, tamponade, arteriovenous fistula or pseudoaneurysm, persistent (resolving during follow up) or permanent (if not resolved at end of follow up, but \>12 months) phrenic nerve palsy, bleeding with a decrease in haemoglobin of at least 2 g / dl or any other state requiring prolongation of hospitalization are considered major complications.
The duration of the project and follow-up. The study is expected to last two years. Approximately 50 patients will be enrolled, with one year follow-up. All patients will have follow-up visits in an out-patient clinic at least 3 and 12 months post PVI. Additionally at 6 weeks, 6 and 9 months post ablation telephone follow-up will be conducted by the study coordinator using standardized questionnaire.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Paroxysmal Atrial Fibrillation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cryoballoon ablation without contrast
Cryoballoon ablation without contrast
Group Type
EXPERIMENTAL
Cryoballoon ablation without contrast
Intervention Type
DEVICE
Cryoballoon ablation without contrast
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cryoballoon ablation without contrast
Cryoballoon ablation without contrast
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with paroxysmal AF - episodes lasting up to 7 days or cardioverted before this time
* At least 4 AF attacks in the last 12 months
* Informed consent for participation in the study
* Age \> 18 and \< 70 years
* Left atrium diameter (PLAX) \< 4,5 cm and left atrial area \< = 30 cm2
* Left ventricle ejection fraction \> 45%
* Four separate veins visualised in computed tomography prior to the ablation
* At least 4 AF attacks in the last 12 months
* Informed consent for participation in the study
* Age \> 18 and \< 70 years
* Left atrium diameter (PLAX) \< 4,5 cm and left atrial area \< = 30 cm2
* Left ventricle ejection fraction \> 45%
* Four separate veins visualised in computed tomography prior to the ablation
Exclusion Criteria
* Withdrawal of consent for the procedure
* Documented typical atrial flutter prior to the ablation
* Thrombus in left atrium
* GFR \< 60 ml/min
* Pregnancy
* Common trunk of left or right pulmonary veins documented on computed tomography (preferred) or by means of other imaging methods
* Other conditions that preclude AF ablation including: infection, uncontrolled hyperthyroidism, significant anaemia and thrombocytopenia, acute cardiac / internist / surgical conditions
* Documented typical atrial flutter prior to the ablation
* Thrombus in left atrium
* GFR \< 60 ml/min
* Pregnancy
* Common trunk of left or right pulmonary veins documented on computed tomography (preferred) or by means of other imaging methods
* Other conditions that preclude AF ablation including: infection, uncontrolled hyperthyroidism, significant anaemia and thrombocytopenia, acute cardiac / internist / surgical conditions
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Cardiology, Warsaw, Poland
OTHER
Sponsor Role
collaborator
Medicover Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pawel Derejko
Head of Cardiology Department
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pawel Derejko, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Medicover Hospital, Warsaw, Poland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medicover Hospital
Warsaw, , Poland
Site Status
RECRUITING
National Institute of Cardiology
Warsaw, , Poland
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Poland
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1_2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Multi-electrode Radiofrequency Balloon Catheter Use for the Isolation of the Pulmonary Veins.
NCT03437733
COMPLETED
NA
Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation
NCT00247780
COMPLETED
PHASE4
Single Versus Double Cryoballoon Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation
NCT03003975
COMPLETED
NA
Comparison of Fluoroscopy-only vs. Electroanatomic Mapping Strategies for Pulmonary Vein Isolation With Balloon-based Pulsed-field Ablation
NCT07118046
RECRUITING
NA
A Study of Strategies for Electrical Isolation of Pulmonic Veins for Curative Treatment of Atrial Fibrillation
NCT00434694
COMPLETED
NA
Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomatic Paroxysmal AF
NCT04704986
ACTIVE_NOT_RECRUITING
PHASE4
Cryoballoon Ablation in Patients With Longstanding Persistent Atrial Fibrillation
NCT02294929
UNKNOWN
NA
Left Atrial Arrhythmia Substrate Identification After Confirmed durABLE Pulmonary Vein Isolation
NCT04111731
COMPLETED
NA
Pulsed Field or Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation in Heart Failure
NCT07181291
COMPLETED
Ganglionated Plexi Ablation Combined With Pulmonary Vein Isolation
NCT01703247
COMPLETED
PHASE2
Incidence and Duration of Unintentional Neuromodulation Effects After Pulmonary Vein Isolation in Patients With Atrial Fibrillation.
NCT05677516
UNKNOWN
PVI Using Cryoablation Alone in Paroxysmal AF Patients Converted From Persistent AF With Dofetilide
NCT01877486
WITHDRAWN
PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF)
NCT00774566
COMPLETED
PHASE4
Reduction of Radiation Dose and Contrast Use During Cryoballoon Pulmonary Vein Isolation
NCT03786822
COMPLETED
NA
Pulmonary Vein Isolation With the Single Shot Endoscopic Ultra-Compliant PFA Balloon for the Treatment of AF
NCT06828939
RECRUITING
NA
CLOSE-guided Pulmonary Vein Isolation Using High Power and Stable RF Applications
NCT04122963
COMPLETED
NA
Multicenter Registry of Atrial Fibrillation Ablation With Radiofrequency Balloon Catheter
NCT06333327
RECRUITING
Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation
NCT07021313
RECRUITING
NA
FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation
NCT01490814
COMPLETED
NA
A Clinical Study on the Use of a Domestically Produced Cryoablation System Combined With Balloon Cryoablation Technology for the Treatment of Paroxysmal Atrial Fibrillation
NCT07036068
NOT_YET_RECRUITING
NA
Simplified Pulmonary Vein Isolation Using singLe Catheter and IntraCardiac Echocardiography
NCT04923009
UNKNOWN
PHASE4
Left Atrial Posterior Wall and PV Isolation Using Cryoballoon for Treatment of Persistent AF
NCT04505163
UNKNOWN
NA
Cryoenergy Or Radiofrequency for Pulmonary Vein Isolation
NCT00969735
COMPLETED
PHASE4
Cardioneuroablation for the Treatment of Vagally-mediated Atrial Fibrillation.
NCT05461859
COMPLETED
Unexcitability Along the Ablation as an Endpoint for Atrial Fibrillation Ablation
NCT01724437
COMPLETED
NA